Lenz Therapeutics, Inc. 8-K Filing
Ticker: LENZ · Form: 8-K · Filed: Dec 12, 2025 · CIK: 1815776
| Field | Detail |
|---|---|
| Company | Lenz Therapeutics, Inc. (LENZ) |
| Form Type | 8-K |
| Filed Date | Dec 12, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Lenz Therapeutics, Inc. (ticker: LENZ) to the SEC on Dec 12, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.00001 (ich registered Common Stock, par value $0.00001 per share LENZ The Nasdaq Stock Market).
How long is this filing?
Lenz Therapeutics, Inc.'s 8-K filing is 2 pages with approximately 613 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 613 words · 2 min read · ~2 pages · Grade level 12.4 · Accepted 2025-12-12 16:15:09
Key Financial Figures
- $0.00001 — ich registered Common Stock, par value $0.00001 per share LENZ The Nasdaq Stock Market
Filing Documents
- lenz-20251212.htm (8-K) — 25KB
- 0001815776-25-000077.txt ( ) — 143KB
- lenz-20251212.xsd (EX-101.SCH) — 2KB
- lenz-20251212_lab.xml (EX-101.LAB) — 23KB
- lenz-20251212_pre.xml (EX-101.PRE) — 13KB
- lenz-20251212_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. LENZ Therapeutics, Inc. ("the Company") is aware of a recent adverse event report submitted to the U.S. Food and Drug Administration's ("FDA") Adverse Event Reporting System ("FAERS") database describing a retinal tear in a patient using VIZZ (aceclidine ophthalmic solution) 1.44%. While FAERS data does not equate to a causal relationship, the Company takes all safety reports seriously and promptly reviewed the case in accordance with our pharmacovigilance procedures. The patient had a significant history of underlying retinal pathology, including bilateral lattice degeneration, prior peripheral laser treatment, and a previous retinal tear. According to the report, the patient had not undergone a recent peripheral retinal examination before initiating therapy. Several days after starting treatment, but on a non-dosing day, the patient observed a change in vision and was subsequently diagnosed with a retinal tear, and received laser retinopexy. The patient is recovering well. Independent retina specialists consulted as part of our assessment noted that the patient had multiple pre-existing risk factors that make spontaneous retinal events more likely, and therefore a causal relationship to VIZZ remains uncertain. Retinal tears occur naturally at an estimated incidence of approximately 25 per 100,000 individuals per year. As VIZZ use continues to expand in real-world settings, isolated retinal events may occur. This initial report, involving a patient with substantial baseline risk, does not alter our current safety expectations for VIZZ. Going forward, the Company does not expect to provide this level of case detail for each individual report, but felt it was appropriate for this initial instance.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 12, 2025 LENZ THERAPEUTICS, INC. By: /s/ Evert Schimmelpennink Name: Evert Schimmelpennink Title: Chief Executive Officer (Principal Executive Officer)